Technology
MetalloBio’s primary focus is on the development of our pipeline compounds toward the clinic, with the aim of ultimately bringing a new class of antimicrobial therapeutic to the market for patient benefit. In parallel, we are working with partners to demonstrate efficacy in a wide range of potential non-therapeutic applications.
UTIs affect around 150 million people worldwide, of these:
80% are associated with catheterisation,
19.7% are acquired in hospital,
Annual NHS treatment costs total £434 million.
VAP causes 10,000-20,000 infections in the UK annually:
Mortality risk is increased by 30%
Annual NHS treatment costs total £10-20k per patient.
Coatings
Our compounds retain their activity when incorporated into a range or materials suitable for application as a coating for medical devices such as catheters, stents and orthopedic implants.
A new antimicrobial coating for catheters and endotracheal tubes could help to prevent medical device associated infections such as catheter-associated urinary tract infections (CAUTIs) and ventilator-associated pneumonia (VAP).
Potential to underpin radical development in:
Advanced personal protective equipment (PPE)
Food packaging
Functionalised textiles
Polymers
We have shown that our antimicrobial additives can be incorporated into a number of polymeric materials, for example latexes, with efficacy against WHO priority pathogens observed at loading levels significantly lower than market leading products.
Paints & Laquers
We are exploring the potential to incorporate our compounds into paints for deployment in settings where an extensive antimicrobial surface is desirable, such as walls and floors in medical care settings, food processing and manufacturing locations.
Photo by Stephanie Ho (Pexels)